IRVINE, CA -- (Marketwire) -- 10/14/08 -- BIOLASE Technology, Inc. (NASDAQ: BLTI) announced today the formalization of its luminary group and the establishment of a luminary advisory board as another step in its ongoing customer satisfaction, service and training campaign. "The focus on customer satisfaction is a key part of our strategy to address issues that slowed the Company's growth from 2004 through 2007," CEO Jake St. Philip said.
The Company formalized its relationships with a world class group of key Waterlase® Dentist luminaries to help it launch a new clinical training methodology and provide ongoing clinical support for its customers. In addition, a special training Advisory Board has been formed within this group to oversee the development of new training materials and technology support tools that will set a new standard in laser dentistry clinical training.
The new training Advisory Board and key luminaries are fulfilling the need to provide expertise and focus in the field of dental laser training and will complement the current academic and World Clinical Laser Institute (WCLI) luminaries around the world.
The Training Luminary Team brings together many of the most talented, practicing Waterlase Dentists: Dr. Gerald Bittner, Dr. Patrick Broome, Dr. Bruce Cassis, Dr. William Chen, Dr. David Eshom, Dr. Howard Golan, Dr. Michael Koceja, Dr. Brad Labrecque, Dr. Robert Lowe, Dr. Louis Malcmacher, Dr. Fred Margolis, Dr. Stewart Rosenberg, and Dr. Chris Walinski.
St. Philip noted that the mission of the new luminary team is to work with the Company to:
-- Deliver a standard and consistent training curriculum and methodology -- Maintain direct contact with customers through each stage of training to ensure optimized learning -- Help customers maximize their revenue potential through rapid and continuous adoption of Waterlase Dentistry(TM) hard and soft tissue procedures
After taking the helm in January of 2008, St. Philip concluded that a greatly enhanced focus on customer satisfaction and service was going to be a key to the Company's success. One of his early key hires was Melinda Floros, Vice President, Global Customer Support. Floros is an experienced customer relations executive who came to the Company from Irvine, CA-based IntraLase Corporation. Floros said, "To ensure we approached our initial improvement efforts from the customers' point of view, we initiated and concluded a comprehensive customer survey, which indicated specific needs in improving our service and training programs. Formalizing this Luminary Team and the development of the Advisory Board is an important step in addressing those specific issues and ensuring our efforts are efficient and in line with our customer needs."
Other customer satisfaction, service and support initiatives include:
-- On-going regional one-day clinical refresher courses at no charge to the customer, which were launched in the third quarter -- The development of a clinical training website for ongoing interactive learning -- to be previewed at this week's American Dental Association (ADA) Annual Session in San Antonio -- Practice management consulting and marketing
"In our focus on execution, we have improved sales process, strengthened our relationship with Henry Schein, Inc. (NASDAQ: HSIC), have begun to segment the Company's marketing approach, and recently launched a new product and software upgrade," St. Philip said. "In addressing another key execution initiative, we are excited to have the guidance of our Luminary Group and Advisory Board in raising the standard of training, service and support."
About BIOLASE Technology, Inc.
BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.
For further information, contact:
David M. Mulder
Chief Financial Officer
BIOLASE Technology, Inc.
Allen & Caron